康泰生物与阿斯利康签署许可终止协议

Core Viewpoint - 康泰生物 has terminated its licensing agreement with AstraZeneca for the development, production, and commercialization of the ChAdOx1 adenovirus vector COVID-19 vaccine due to significant changes in domestic and international market conditions and vaccine strains [1] Group 1 - 康泰生物 signed a licensing agreement with AstraZeneca UK Limited on August 20, 2020, granting exclusive rights for the COVID-19 vaccine in mainland China [1] - The decision to terminate the licensing agreement was made after mutual consultation between both parties [1] - A termination agreement has been signed, which nullifies all rights and obligations under the original licensing agreement effective immediately upon signing [1]